Clinical effect of polaprezine granules combined with hydrotalcite tablets in treatment of bile reflux gastritis with intestinal metaplasia
YANG Linhui1, GUO Zhijuan2, XIANG Shu1
1. Department of Gastroenterology, Chongqing Municipal Corps Hospital of PAP,Chongqing 400061,China; 2. The Third Medical Center of PLA General Hospital, Beijing 100039,China
Abstract：Objective To investigate clinical effect of polaprezine granules combined with hydrotalcite tablets in treatment of bile reflux gastritis(BRG) with intestinal metaplasia.Methods Seventy-six patients with BRG with intestinal metaplasia were included in this study. They were selected to be divided into observation group and control group via the random number table,with 38 cases in each. They were all diagnosed by endoscopy and BRG with intestinal metaplasia were diagnosed by pathological examination.The control group was treated with hydrotalcite tablets,while the observation group additionally received polaprezine granules based on the control group. Before and after therapy,differences of symptoms cores,gastroscopy cores and gastric mucosa chronic inflammation pathological histology score , improvement rate of intestinal metaplasia ,and incidence of adverse drug reactions between two groups were compared.Results After treatment,the symptoms cores,gastroscopy cores and gastric mucosa chronic inflammation pathological histology score were significantly lower than those in control group,with statistically significant difference(P<0.05). The gastric mucosa intestinal metaplasia score of observation group were higher than those in control group with statistically difference(1.41±0.63 vs. 1.79±0.59, P<0.05). The improvement rate of intestinal metaplasia was 52.6%(20/38)in observation group and 15.8%(6/38)in control group, so the difference was statistically significant(P<0.05).There was no severe adverse drug reaction in both group and no statistically significant difference between them.Conclusions Polaprezine granules combined with hydrotalcite tablets can improve clinical symptoms and prognosis of gastric mucosa pathology of BRG with intestinal metaplasia.
Gomez J M, Wang A Y. Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm [J]. Gastroenterol Hepatol(NY) , 2014, 10(6):369-378.
[8]
Choi A Y, Strate L L, Fix M C,et al . Association of gastric intestinal metaplasia and east asian ethnicity with the risk of gastric adenocarcinoma in a U. S. population[J].Gastrointest Endosc, 2018, 87(4) : 1023-1028.
2021, Vol. 32 
